TY - JOUR
T1 - The predicted lifetime costs and health consequences of calcium and vitamin D supplementation for fracture prevention—the impact of cardiovascular effects
T2 - the impact of cardiovascular effects
AU - Hagen, G.
AU - Wisløff, T.
AU - Sønbø Kristiansen, Ivar
N1 - Export Date: 22 March 2017 CODEN: OSINE
PY - 2016/6
Y1 - 2016/6
N2 - Summary: Some studies indicate that calcium supplementation increases cardiovascular risk. We assessed whether such effects could counterbalance the fracture benefits from supplementation. Accounting for cardiovascular outcomes, calcium may cause net harm and would not be cost-effective. Clinicians may do well considering cardiovascular effects when prescribing calcium supplementation. Introduction: Accounting for possible cardiovascular effect of calcium and vitamin D supplementation (CaD), the aims of this study were to assess whether CaD on balance would improve population health and to evaluate the cost-effectiveness of such supplementation. Methods: We created a probabilistic Markov simulation model that was analysed at the individual patient level. We analysed 65-year-old Norwegian women with a 2.3 % 10-year risk of hip fracture and a 9.3 % risk of any major fracture according to the WHO fracture risk assessment tool (FRAX®). Consistent with a recent Cochrane review, we assumed that CaD reduces the risk of hip, vertebral, and wrist fractures by 16, 11, and 5 %, respectively. We included the increased risk of acute myocardial infarction (AMI) and stroke under a no-, medium-, and high-risk scenario. Results: Assuming no cardiovascular effects, CaD supplementation produces improved health outcomes resulting in an incremental gain of 0.0223 quality-adjusted life years (QALYs) and increases costs by €322 compared with no treatment (cost-effectiveness ratio €14,453 per QALY gained). Assuming a Norwegian cost-effectiveness threshold of €60,000 per QALY, CaD is likely to be considered a cost-effective treatment alternative. In a scenario with a medium or high increased risk of cardiovascular events, CaD produces net health losses, respectively, −0.0572 and −0.0784 QALY at additional costs of €481 and €1033. Conclusions: We conclude that the magnitude of potential cardiovascular side effects is crucial for the effectiveness and cost-effectiveness of CaD supplementation in elderly women. © 2016, International Osteoporosis Foundation and National Osteoporosis Foundation.
AB - Summary: Some studies indicate that calcium supplementation increases cardiovascular risk. We assessed whether such effects could counterbalance the fracture benefits from supplementation. Accounting for cardiovascular outcomes, calcium may cause net harm and would not be cost-effective. Clinicians may do well considering cardiovascular effects when prescribing calcium supplementation. Introduction: Accounting for possible cardiovascular effect of calcium and vitamin D supplementation (CaD), the aims of this study were to assess whether CaD on balance would improve population health and to evaluate the cost-effectiveness of such supplementation. Methods: We created a probabilistic Markov simulation model that was analysed at the individual patient level. We analysed 65-year-old Norwegian women with a 2.3 % 10-year risk of hip fracture and a 9.3 % risk of any major fracture according to the WHO fracture risk assessment tool (FRAX®). Consistent with a recent Cochrane review, we assumed that CaD reduces the risk of hip, vertebral, and wrist fractures by 16, 11, and 5 %, respectively. We included the increased risk of acute myocardial infarction (AMI) and stroke under a no-, medium-, and high-risk scenario. Results: Assuming no cardiovascular effects, CaD supplementation produces improved health outcomes resulting in an incremental gain of 0.0223 quality-adjusted life years (QALYs) and increases costs by €322 compared with no treatment (cost-effectiveness ratio €14,453 per QALY gained). Assuming a Norwegian cost-effectiveness threshold of €60,000 per QALY, CaD is likely to be considered a cost-effective treatment alternative. In a scenario with a medium or high increased risk of cardiovascular events, CaD produces net health losses, respectively, −0.0572 and −0.0784 QALY at additional costs of €481 and €1033. Conclusions: We conclude that the magnitude of potential cardiovascular side effects is crucial for the effectiveness and cost-effectiveness of CaD supplementation in elderly women. © 2016, International Osteoporosis Foundation and National Osteoporosis Foundation.
KW - Calcium
KW - Cardiovascular
KW - Cost-effectiveness
KW - Fracture
KW - Osteoporosis
KW - Primary prevention
KW - Quality-Adjusted Life Years
KW - Calcium, Dietary/administration & dosage
KW - Cardiovascular Diseases/epidemiology
KW - Humans
KW - Risk Factors
KW - Vitamin D/administration & dosage
KW - Dietary Supplements/economics
KW - Cost-Benefit Analysis
KW - Fractures, Bone/economics
KW - Female
KW - Aged
U2 - 10.1007/s00198-016-3495-9
DO - 10.1007/s00198-016-3495-9
M3 - Journal article
C2 - 26846776
SN - 0937-941X
VL - 27
SP - 2089
EP - 2098
JO - Osteoporosis International
JF - Osteoporosis International
IS - 6
ER -